In vitro Antibacterial Activity of Doripenem against Gram-Negative Blood Isolates in a Korean Tertiary Care Center
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Doripenem is the most recently introduced antimicrobial agent of the carbapenem class. It is a valuable therapeutic option in the context of increasing antimicrobial resistance to imipenem and meropenem among gram-negative bacilli (GNB) clinical isolates. However, clinicians are usually reluctant to prescribe doripenem, because susceptibility to doripenem is not automatically reported by most clinical laboratories and the in vitro activity of doripenem against clinically significant GNB isolates remains uncertain. Materials and Methods: We investigated the in vitro antibacterial activity of doripenem in GNB blood isolates in a tertiary care center. Over a period of 10 months, 212 adult bacteremia cases were treated at the study hospital. Doripenem susceptibility testing was performed for the 212 blood isolates by the disk diffusion method, and clinical data were collected. Results: Among the blood isolates, the rate of doripenem resistance (7.5%) was lower than that of imipenem (12.9%) or other anti- GNB antimicrobial agents, except amikacin (2.1%). Almost all imipenem-susceptible GNB blood isolates (181/182, 99.5%) were susceptible to doripenem. Whereas doripenem resistance was rarely observed in Enterobacteriaceae (2/181, 1.1%), it was frequently observed in patients with non-fermentatative GNB (12/27, 44.4%), hospital-acquired infections (7/27, 25.9%), and pneumonia (11/49, 22.4%). Conclusion: Doripenem exhibited more potent in vitro activity against GNB blood isolates than other anti-GNB antimicrobial agents in a tertiary care center where it was infrequently prescribed compared with other carbapenems. However, its clinical utility may be limited due to the increasing number of carbapenem-resistant non-fermentative GNB infections.
Abstract
Background: Doripenem is the most recently introduced antimicrobial agent of the carbapenem class. It is a valuable therapeutic option in the context of increasing antimicrobial resistance to imipenem and meropenem among gram-negative bacilli (GNB) clinical isolates. However, clinicians are usually reluctant to prescribe doripenem, because susceptibility to doripenem is not automatically reported by most clinical laboratories and the in vitro activity of doripenem against clinically significant GNB isolates remains uncertain. Materials and Methods: We investigated the in vitro antibacterial activity of doripenem in GNB blood isolates in a tertiary care center. Over a period of 10 months, 212 adult bacteremia cases were treated at the study hospital. Doripenem susceptibility testing was performed for the 212 blood isolates by the disk diffusion method, and clinical data were collected. Results: Among the blood isolates, the rate of doripenem resistance (7.5%) was lower than that of imipenem (12.9%) or other anti- GNB antimicrobial agents, except amikacin (2.1%). Almost all imipenem-susceptible GNB blood isolates (181/182, 99.5%) were susceptible to doripenem. Whereas doripenem resistance was rarely observed in Enterobacteriaceae (2/181, 1.1%), it was frequently observed in patients with non-fermentatative GNB (12/27, 44.4%), hospital-acquired infections (7/27, 25.9%), and pneumonia (11/49, 22.4%). Conclusion: Doripenem exhibited more potent in vitro activity against GNB blood isolates than other anti-GNB antimicrobial agents in a tertiary care center where it was infrequently prescribed compared with other carbapenems. However, its clinical utility may be limited due to the increasing number of carbapenem-resistant non-fermentative GNB infections.
참고문헌 (19)
- Baldwin CM, "Meropenem:a review of its use in the treatment of serious bacterial infections", Drugs, 68, pp.803~838 (2008)
- Rodloff AC, "Two decades of imipenem therapy", J Antimicrob Chemother, 58, pp.916~929 (2006)
- Pogue JM, "Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance, and management", Expert Rev Anti Infect Ther, 11, pp.383~393 (2013)
- Kanj SS, "Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa", Mayo Clin Proc, 86, pp.250~259 (2011)
- Jones RN, "Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations", J Antimicrob Chemother, 54, pp.144~154 (2004)
- Mushtaq S, "Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants and transconjugants and resistance selection potential", Antimicrob Agents Chemother, 48, pp.3086~3092 (2004)
- Fritsche TR, "Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003)", Clin Microbiol Infect, 11, pp.974~984 (2005)
- Castanheira M, "Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp", Diagn Microbiol Infect Dis, 63, pp.426~433 (2009)
- Livermore DM, "Doripenem: antimicrobial profile and clinical potential", Diagn Microbiol Infect Dis, 63, pp.455~458 (2009)
- Hagihara M, "Predicting doripenem susceptibility based on meropenem and imipenem interpretation for Pseudomonas aeruginosa", Diagn Microbiol Infect Dis, 72, pp.258~262 (2012)
- Lee H, "Antimicrobial activity of doripenem and other carbapenems against gram-negative pathogens from Korea", Microb Drug Resist, 17, pp.37~45 (2011)
- Dong SX, "Activities of doripenem against nosocomial bacteremic drug-resistant Gram-negative bacteria in a medical center in Taiwan", J Microbiol Immunol Infect, 45, pp.459~464 (2012)
- Friedman ND, "Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections", Ann Intern Med, 137, pp.791~797 (2002)
- Bone RC, "Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP", SCCM Consensus Conference Committee. American College of Chest Physicians, Chest, pp.1992, 101[DOI]
- Clinical and Laboratory Standards Institute, "Performance standards for antimicrobial susceptibility testing: 24th informational supplement, 2014 Document M100-S24", CLSI, ~ (2014)
- Rice DA, "Activity of doripenem versus comparators in subjects with baseline bacteremia in six pooled phase 3 clinical trials", Int J Antimicrob Agents, 41, pp.388~392 (2013)
- Mustafa M, "A PROspective study on the Usage patterns of Doripenem in the Asia-Pacific region (PROUD study)", Int J Antimicrob Agents, 43, pp.353~360 (2014)
- Luyt CE, "Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia", Antimicrob Agents Chemother, 58, pp.1372~1380 (2014)
- Jones RN, "Activities of doripenem (S-4661) against drug-resistant clinical pathogens", Antimicrob Agents Chemother, 48, pp.3136~3140 (2004)